News
-
-
PRESS RELEASE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. announces FDA conditional approval renewal of Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a crofelemer tablet, is available from major U.S. veterinary distributors -
-
PRESS RELEASE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals announces acceptance of late-breaking abstract on crofelemer results for breast cancer patients in OnTarget trial, presented at SABCS 2024 -
-
PRESS RELEASE
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Napo Pharmaceuticals announces abstracts for two investigator-initiated studies on crofelemer for chronic refractory diarrhea patients, presented at ACG 2024. Jaguar CEO Lisa Conte comments on crofelemer's clinical robustness and impact on IBS-D patients -
-
-
-
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. grants restricted stock units to new employees as inducement for employment. RSUs vest over one to three years. Company focused on developing pharmaceuticals from rainforest plants for gastrointestinal distress
